Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - randomized


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.5005
TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations

Joaquin Mateo · Nuria Porta · U. McGovern · Tony Elliott · Robert Jones · Isabel Syndikus · Christy Ralph · Suneil Jain · Mohini Varughese · O. Parikh · Simon J. Crabb · Susana Miranda · George Seed · Claudia Bertan · Aude Espinasse · Peter Chatfield · Diletta Bianchini · Emma Hall · Suzanne Carreira · Johann S. de Bono ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.1005
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.

Robert Hugh Jones · Margherita Carucci · Angela C. Casbard · Rachel Butler · Fouad S Alchami · Catherine Jane Bale · Pavel Bezecny · Johnathan Joffe · Sarah Moon · Chris Twelves · Ramachandran Venkitaraman · Simon Waters · Sacha J Howell ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.9000
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Kazuhiko Nakagawa · Edward B. Garon · Takashi Seto · Makoto Nishio · Santiago Ponce Aix · Chao-Hua Chiu · Keunchil Park · Silvia Novello · Ernest Nadal · Fumio Imamura · Kiyotaka Yoh · Jin-Yuan Shih · Kwok Hung Au · Denis Moro-Sibilot · Sotaro Enatsu · Annamaria Zimmermann · Bente Frimodt-Moller · Carla M. Visseren Grul · Martin Reck ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.3501
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

Timothy Iveson · Alberto Sobrero · Takayuki Yoshino · Ioannis Sougklakos · Fang-Shu Ou · Jeffery P. Meyers · Qian Shi · Mark P Saunders · Roberto Labianca · Takeharu Yamanaka · Ioannis Boukovinas · Niels Henrik Hollander · Valter Torri · Kentaro Yamazaki · Vassilis Georgoulias · Sara Lonardi · Andrea Harkin · Gerardo Rosati · James Paul ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.19.01507
Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer

Carryn M Anderson · Christopher M Lee · Deborah P Saunders · Amarinthia Curtis · Neal Dunlap · Chaitali Nangia · Arielle S Lee · Sharon M Gordon · Philip Kovoor · Roberto Arevalo-Araujo · Voichita Bar-Ad · Abhinand Peddada · Kyle Colvett · Douglas Miller · Anshu K Jain · James Wheeler · Dukagjin Blakaj · Marcelo Bonomi · Sanjiv S Agarwala · Madhur Garg · Francis Worden · Jon Holmlund · Jeffrey M Brill · Matt Downs · Stephen T Sonis · Sanford Katz · John M Buatti ·

Medicine
PDF

Highly Related Keywords from randomized

Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals